Author:
De Santis R.,Cagnoli G.,Rinaldi B.,Consonni D.,Conti Beatrice,Eoli M.,Liguori A.,Cosentino M.,Carrafiello G.,Garrone O.,Giroda M.,Cesaretti C.,Sfondrini M.S.,Gambini D.,Natacci F.
Abstract
AbstractNeurofibromatosis type 1 (NF1) is an autosomal dominant condition caused by neurofibromin haploinsufficiency due to pathogenic variants in the NF1 gene. Tumor predisposition has long been associated with NF1, and an increased breast cancer (BC) incidence and reduced survival have been reported in recent years for women with NF1. As breast density is another known independent risk factor for BC, this study aims to evaluate the variability of breast density in patients with NF1 compared to the general population. Mammograms from 98 NF1 women affected by NF1, and enrolled onto our monocentric BC screening program, were compared with those from 300 healthy subjects to verify differences in breast density. Mammograms were independently reviewed and scored by a radiologist and using a Computer-Aided Detection (CAD) software. The comparison of breast density between NF1 patients and controls was performed through Chi-squared test and with multivariable ordinal logistic models adjusted for age, body mass index (BMI), number of pregnancies, and menopausal status.breast density was influenced by BMI and menopausal status in both NF1 patients and healthy subjects. No difference in breast density was observed between NF1 patients and the healthy female population, even after considering the potential confounding factors.Although NF1 and a highly fibroglandular breast are known risk factors of BC, in this study, NF1 patients were shown to have comparable breast density to healthy subjects. The presence of pathogenic variants in the NF1 gene does not influence the breast density value.
Funder
Università degli Studi di Milano
Publisher
Springer Science and Business Media LLC
Reference36 articles.
1. Uusitalo E, Leppävirta J, Koffert A, Suominen S, Vahtera J, Vahlberg T et al (2015) Incidence and mortality of neurofibromatosis: a total population study in Finland. J Invest Dermatol 135:904–906. https://doi.org/10.1038/jid.2014.465
2. Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM et al (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152A:327–332. https://doi.org/10.1002/ajmg.a.33139
3. Gutmann DH, Collins FS (1993) The neurofibromatosis type 1 gene and its protein product, neurofibromin. Neuron 10:335–343. https://doi.org/10.1016/0896-6273(93)90324-k
4. Anastasaki C, Orozco P, Gutmann DH (2022) RAS and beyond: the many faces of the neurofibromatosis type 1 protein. Dis Models Mech 15:dmm049362. https://doi.org/10.1242/dmm.049362
5. Friedman JM (1993) In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, Gripp KW, GeneReviews® et al (eds) Neurofibromatosis 1. University of Washington, Seattle, Seattle (WA)